Source:http://linkedlifedata.com/resource/pubmed/id/15283853
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2004-7-30
|
pubmed:abstractText |
Th2 cytokines, commonly detected in burn patients, have been shown as inhibitors for the generation of Th1 cells that are essential for the host's resistance against herpes simplex virus type 1 (HSV-1) infection. In this study, the possibility of immunological treatment through the regulation of Th1/Th2 responses was examined in two kinds of human severe combined immunodeficiency (SCID) chimera models reflecting human immune functions. SCID mice injected with a mixture of PBMC from a healthy donor and Th2 cells experimentally generated from the same healthy PBMC (Th2 SCID chimeras) were more susceptible to HSV-1 infection when compared with SCID mice injected with healthy donor PBMC (healthy SCID chimeras). When Th2 SCID chimeras were individually treated with human IL-12 (hIL-12) or human soluble IL-4 receptor (hsIL-4R), hIFN-gamma was not produced in their sera after antihuman CD3 mAb stimulation. However, hIFN-gamma production in sera of Th2 SCID chimeras treated with the combination therapy of hIL-12 and hsIL-4R was recovered at levels observed in healthy SCID chimeras. When Th2 SCID chimeras infected with HSV-1 were treated with saline, hIL-12, hsIL-4R or a combination of hIL-12 and hsIL-4R, 13%, 13%, 25% or 100% of them survived, respectively. Also, Th1 responses (hIFN-gamma production) were demonstrated in Th2 SCID chimeras that became resistant against HSV-1 infection after the combination treatment. These results suggest that individuals whose Th2 cells predominated may be immunologically controlled by the combination treatment between a Th1 response inducer and a Th2 response inhibitor.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0818-9641
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
82
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
421-6
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:15283853-Animals,
pubmed-meshheading:15283853-Burns,
pubmed-meshheading:15283853-Chimera,
pubmed-meshheading:15283853-Disease Models, Animal,
pubmed-meshheading:15283853-Drug Therapy, Combination,
pubmed-meshheading:15283853-Herpes Simplex,
pubmed-meshheading:15283853-Herpesvirus 1, Human,
pubmed-meshheading:15283853-Humans,
pubmed-meshheading:15283853-Interferon-gamma,
pubmed-meshheading:15283853-Interleukin-12,
pubmed-meshheading:15283853-Male,
pubmed-meshheading:15283853-Mice,
pubmed-meshheading:15283853-Mice, SCID,
pubmed-meshheading:15283853-Receptors, Interleukin-4,
pubmed-meshheading:15283853-Recombinant Proteins,
pubmed-meshheading:15283853-Th2 Cells
|
pubmed:year |
2004
|
pubmed:articleTitle |
Effect of IL-12 and soluble IL-4 receptor on the herpesvirus infection in human SCID chimeras whose Th2 cells predominate.
|
pubmed:affiliation |
Department of Internal Medicine, The University of Texas Medical Branch, Galveston 77555, USA.
|
pubmed:publicationType |
Journal Article
|